Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, discusses the role of positron emission tomography (PET) adapted therapy in patients with Hodgkin lymphoma. Various studies such as the Phase III HD17 trial (NCT01356680) has shown PET to be useful in assessing whether radiotherapy can be omitted. Further data is required to assess whether PET plus new therapies such as brentuximab vedotin or checkpoint inhibitors such as pembrolizumab and nivolumab is equally as effective. Further technological improvements in radiotherapy may also lower radiotherapy-associated toxicities, potentially reducing the need for omitting radiotherapy in the future. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).